Flucytosine monotherapy for cryptococcosis

Clinical Infectious Diseases

Volumn 27, Issue 2, 1998, Pages 260-264

  Hospenthal, Duane R ^a   Bennett, John E ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BONE MARROW TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYPTOCOCCOSIS; DRUG INDICATION; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RELAPSE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0031928924     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/514669     Document Type: Article

References (5)

1. Butler WT, Alling DW, Spickard A, Utz JP. Diagnostic and prognostic value of clinical and laboratory findings in cryptococcal meningitis. A follow-up study of forty patients. N Engl J Med 1964;270:59-67.
2. Sarosi GA, Parker JD, Doto IL, Tosh FE. Amphotericin B in cryptococcal meningitis. Long-term results of treatment. Ann Intern Med 1969;71: 1079-87.
3. Beine JP, Lontie M, Vandepitte J. Cryptococcal meningoencephalitis and 5-fluorocytosine. BMJ 1971;2:107.
4. Pass RJ, Perkins RL. 5-Fluorocytosine in the treatment of cryptococcal and candida mycoses. Ann Intern Med 1971;74:535-9.
5. McDonald R, Greenberg EN, Kramer R. Cryptococcal meningitis. Arch Dis Child 1970;45:417-20.